Emerging evidence, supported by clinical responses to immunotherapy and the recapitulation of sensory symptoms in passive transfer models, shows that autoantibodies (AAbs) may drive neuropathic pain. These findings highlight the importance of immune profiling to enhance diagnosis and treatment, and provide molecular insights into broader pain mechanisms in clinical contexts.
Journal article
2026-02-01T00:00:00+00:00
32
101 - 104
3
Humans, Autoantibodies, Neuralgia, Animals